Windlas Biotech Share Price

NSE
WINDLAS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Windlas Biotech
Windlas Biotech Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Windlas Biotech Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
109.93% Gain from 52W Low
1.2
Dividend yield 1yr %
Above industry Median
0.5

Windlas Biotech Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Windlas Biotech Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
195.02 Cr
187 Cr
175.15 Cr
171.28 Cr
162.21 Cr

Windlas Biotech Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
644.42 Cr
523.05 Cr
472.64 Cr
430.7 Cr
331.34 Cr

Windlas Biotech Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
15.58 Cr
15.66 Cr
13.48 Cr
16.99 Cr
15.1 Cr

Windlas Biotech Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
58.19 Cr
42.63 Cr
38.09 Cr
15.74 Cr
23.68 Cr
Windlas Biotech Result Highlights
  • Windlas Biotech Ltd reported a 3.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.4%.

  • Its expenses for the quarter were up by 4.2% QoQ and 22.8% YoY.

  • The net profit decreased 0.5% QoQ and increased 3.2% YoY.

  • The earnings per share (EPS) of Windlas Biotech Ltd stood at 7.4 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Windlas Biotech shareholding Pattern

Promoter
62.5%
Foreign Institutions
1.6%
Mutual Funds
7.1%
Domestic Institutions
10.2%
Public
25.7%
Promoter
62.5%
Foreign Institutions
2%
Mutual Funds
7.6%
Domestic Institutions
9.6%
Public
25.9%
Promoter
62.5%
Foreign Institutions
1.6%
Mutual Funds
8.7%
Domestic Institutions
10.3%
Public
25.6%
Promoter
62.8%
Foreign Institutions
1.2%
Mutual Funds
10.4%
Domestic Institutions
11.8%
Public
24.2%
Promoter
62.8%
Foreign Institutions
1.4%
Mutual Funds
10.4%
Domestic Institutions
11.7%
Public
24.1%
Promoter
62.8%
Foreign Institutions
0.8%
Mutual Funds
10.4%
Domestic Institutions
11.5%
Public
24.8%

Windlas Biotech Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
1,013.30
10Day EMA
978.20
12Day EMA
967.70
20Day EMA
940.20
26Day EMA
930.60
50Day EMA
927.80
100Day EMA
929.70
200Day EMA
870.80
5Day SMA
1,014.80
10Day SMA
961.40
20Day SMA
921.90
30Day SMA
874.20
50Day SMA
911.80
100Day SMA
974.90
150Day SMA
954.10
200Day SMA
904.00
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
24432 Rs
58173 Rs
Week Rs
51282 Rs
137166 Rs
Month Rs
44686 Rs
136611 Rs
Resistance & Support
1,044.58
Pivot
Resistance
First Resistance
1,063.77
Second Resistance
1,087.03
Third Resistance
1,106.22
Support
First Support
1,021.32
Second support
1,002.13
Third Support
978.87
Relative Strength Index
67.55
Money Flow Index
67.63
MACD
37.10
MACD Signal
18.38
Average True Range
56.79
Average Directional Index
18.90
Rate of Change (21)
26.77
Rate of Change (125)
25.34

Windlas Biotech Company background

Founded in: 2001
Managing director: Hitesh Windlass
Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001. The Company convertedfrom a Private Limited Company to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited. A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun.The Company is engaged in manufacturing and trading of pharmaceutical products. TheIR manufacturing facilities are located at Dehradun in Uttarakhand. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semiurban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products domestic trade generics and overthecounter (OTC) brands and exports.The Company commenced operations at Dehradun Plant IV in 2010. It provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drugdevice combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and lowsolubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. In 2020, the Company acquired the erstwhile associate Windlas Healthcare.To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and RD, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.In August 2021, the Company made an Initial Public Offer of 8,729,023 Equity Shares by raising capital from public aggregating to Rs 401.53 Crore, comprising a Fresh Issue of 3,586,956 Equity Shares aggregating to Rs 165 Crore and an Offer for Sale of 5,142,067 Equity Shares aggregating to Rs 236.53 Crore.
Read More

Windlas Biotech FAQs

Windlas Biotech share price is ₹1040.5 in NSE and ₹1041.2 in BSE as on 27/3/2025.

Windlas Biotech share price in the past 1-year return was 103.89. The Windlas Biotech share hit a 1-year low of Rs. 495.65 and a 1-year high of Rs. 1198.25.

The market cap of Windlas Biotech is Rs. 2174.68 Cr. as of 27/3/2025.

The PE ratios of Windlas Biotech is 35.49 as of 27/3/2025.

The PB ratios of Windlas Biotech is 4.61 as of 27/3/2025

The Mutual Fund Shareholding in Windlas Biotech was 7.11% at the end of 27/3/2025.

You can easily buy Windlas Biotech shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Windlas Biotech stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -